By Peter Geschek:
The FDA has just approved Johnson & Johnson's (JNJ) Invokana (previously known as canagliflozin), a once-a-day pill to improve glycemic (blood sugar) control in adults with type 2 diabetes.
The Burrill Report submits: The long road to approval for Mannkind's (MNKD) Afrezza inhaled insulin got a little longer March 15, as the FDA asked for more information to support its review of the drug. Afrezza is a powdered insulin for helping adult patients with type 1 and type 2 diabetes mellitus control high blood glucose, also known as hyperglycemia, which is a major cause of diabetes-related complications. An FDA decision on the drug was initially expected by January 16.
EP Vantage submits:In another example of a major global pharmaceutical company promising a hefty sum to a tiny biotech for an early-stage pipeline product, Sanofi-Aventis (SNY) has licensed from CureDM a human proislet peptide (HIP), Pancreate, for up to $335m in milestones plus royalties.
ALAN MORTON DERSHOWITZ is an American lawyer, jurist and political commentator. He has held the Felix Frankfurter professorship at Harvard Law School since 1993. Dershowitz is known for his involvement in high-profile legal cases and as a commentator on the Arab–Israeli conflict.